BiobankCell BiologyBio-Analysis

Contact & Location

Our research projects focus on the ever-increasing prevalence of Obesity affecting millions of people worldwide. The Metabolic Syndrome and its hepatic manifestation, NAFLD-NASH is a key pathological condition triggered by the noxious biochemical pathways of Obesity. Despite the high unmet medical needs, there are currently no approved drugs for treating NAFLD-NASH. The current main recommendation is lifestyle modification, which is only partially effective.

CellMade’s lead product, CLM-101, co-developed along with diagnostic and prognostic biomarker signatures (CLM-BM-001 for T2DM; CLM-BM-002 for CVD and CLM-BM-003 for COPD), is evaluated for indications in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD, NASH <5%), potentially overcoming later development of T2DM and/or CVD and/or COPD.

Our unique approach allows for several levels of cooperation and partnering: (i) Supply of Products and (ii) Services Agreement related to Metabolic Disease Research. Furthermore, we are actively looking for (iii) Research Cooperation’s related to our lead product and associated biomarker portfolio.

Please use this form for complementary information’s or pricing quotations :

Message * :

* obligatory